SILVER SPRING, Md. - The U.S. Food and Drug Administration on Nov. 16 approved Genentech's oral therapy Wilserdly (giredestrant) combined with everolimus for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The agency cleared the regimen four weeks ahead of its target decision date.
Phase 3 Trial Nearly Doubles Progression-Free Survival
"On November 16, 2026, the Food and Drug Administration approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive," the FDA announced. "Median PFS was 10 months (95% CI: 8.1, 12.9) in the giredestrant and everolimus arm and 5.5 months (95% CI: 3.8, 5.6) in the PCET and everolimus arm," the agency stated.
Genentech said the all-oral combination cut the risk of progression or death by 62% compared with standard hormone therapy plus everolimus.
Companion Blood Test Cleared Alongside International Review
"The agency approved FoundationOne Liquid CDx, a blood test, as the companion test to identify patients whose breast cancer has an ESR1 mutation," CURE Today reported. "The application was reviewed under Project Orbis with Health Canada and Israel's Ministry of Health, and the FDA approved it 4 weeks ahead of its goal date," Targeted Oncology reported.
Genentech Chief Medical Officer Levi Garraway said the all-oral regimen lets advanced breast cancer patients take treatment from home.
Safety Warnings and Upcoming Adjuvant Review
Common side effects included mouth sores, rash, fatigue, diarrhea, and nausea, alongside prescribing warnings for slow heart rate and embryo-fetal toxicity. The FDA is also reviewing Wilserdly for early-stage breast cancer under priority review with a Nov. 30 target date.



